Milan, Italy (December 1, 2025)

Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its attendance at 2025 Eyenovate and FLORetina congress.

The events will be held December 3-7, 2025 in Florence, Italy. The co-founders Marco Ferroni, Chief Executive Officer, and Matteo Cereda, Clinical Advisor, and Vera Scuderi, Chief Operating Officer, will be attending the congresses. MgShell will present its innovation during the Rising Retina Innovation Companies Showcase as disruptive company in the retinal field. Moreover, the company aims is the consolidation of the current relationships and the establishment of the new ones with physicians and strategic partners, in order to implement MgShell Early Adopters Engagement Plan by starting preliminary conversations with vitreoretinal specialists.

About MgShell:

MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.